PT-141 (Bremelanotide) Research Profile

What is PT-141 (Bremelanotide)?

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from the alpha-melanocyte-stimulating hormone (α-MSH) analog melanotan II. The compound was developed by Palatin Technologies through structural modification of melanotan II, specifically removing the C-terminal amide to reduce melanocortin-1 receptor (MC1R) activity while retaining agonist activity at melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R).[3]

Unlike phosphodiesterase type 5 (PDE5) inhibitors that act peripherally on vascular smooth muscle, bremelanotide acts through a central nervous system mechanism. The peptide modulates melanocortin receptor signaling in hypothalamic and limbic brain regions, influencing dopaminergic pathways that underlie sexual motivation, desire, and arousal. This CNS-mediated mechanism of action represented a fundamentally different pharmacological approach to sexual function research.[16]

Bremelanotide (marketed as Vyleesi) received FDA approval in June 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — the first melanocortin receptor agonist approved for this indication.[1] The compound has been evaluated in over 40 clinical trials across approximately 3,500 subjects, establishing one of the most comprehensive clinical datasets for any melanocortin peptide.[11]

Products sold by Improved Peptides are research-grade compounds intended for research use only. They are not the FDA-approved pharmaceutical product.

Mechanism of Action

PT-141’s pharmacological activity is mediated through the melanocortin receptor system, a family of G protein-coupled receptors involved in diverse physiological processes. The compound’s mechanism of action has been characterized across multiple studies:[16]

• MC4R Activation: Bremelanotide acts as an agonist at melanocortin-4 receptors expressed in hypothalamic nuclei (paraventricular nucleus, medial preoptic area) and limbic structures involved in sexual behavior regulation. MC4R activation initiates intracellular cAMP signaling cascades that modulate downstream neurotransmitter release.[16]
• Dopaminergic Modulation: MC4R activation in the medial preoptic area and nucleus accumbens stimulates dopamine release through projections in the mesolimbic pathway. This dopaminergic component is thought to mediate the motivational and desire aspects of sexual function, distinguishing bremelanotide from peripheral vasodilator approaches.[18]
• MC3R Activity: Bremelanotide also demonstrates agonist activity at MC3R, which may contribute to its overall pharmacological profile. MC3R is expressed in hypothalamic regions involved in energy homeostasis and neuroendocrine regulation.[15]
• Central vs. Peripheral Action: The critical distinction from PDE5 inhibitors is bremelanotide’s CNS site of action. While sildenafil and similar compounds enhance peripheral blood flow through nitric oxide/cGMP pathways, bremelanotide modulates the neural circuits governing sexual desire and motivation — a fundamentally upstream mechanism.[3]

Key Research Findings

Female Sexual Function Trials

The clinical development of bremelanotide for female sexual dysfunction represents the most extensive dataset in the compound’s research history. Diamond et al. (2006) published the first clinical evidence of bremelanotide’s effects on subjective sexual response in premenopausal women with sexual arousal disorder, using intranasal administration to demonstrate improvements in desire and arousal measures.[2]

Clayton et al. (2016) conducted the pivotal Phase 2b dose-finding trial, evaluating subcutaneous bremelanotide at multiple dose levels in premenopausal women with HSDD. The study identified 1.75 mg as the optimal dose, demonstrating statistically significant improvements on the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSDS-DAO).[6]

Althof et al. (2019) published responder analyses from the Phase 2b program, establishing minimal clinically important difference (MCID) thresholds for the primary efficacy endpoints and demonstrating that a clinically meaningful proportion of bremelanotide-treated patients exceeded these thresholds compared to placebo.[7]

The pivotal RECONNECT Phase 3 program consisted of two randomized, double-blind, placebo-controlled trials. Kingsberg et al. (2019) reported that bremelanotide 1.75 mg subcutaneous injection produced statistically significant improvements in FSFI desire domain scores and FSDS-DAO total scores versus placebo, meeting both co-primary endpoints in both trials.[8]

Long-term data from the 52-week open-label extension of RECONNECT, also published by Kingsberg et al. (2019), demonstrated sustained efficacy without tachyphylaxis and a safety profile consistent with the controlled trials. No new adverse event signals emerged with extended exposure.[9]

Simon et al. (2022) published prespecified subgroup analyses from the RECONNECT trials, examining bremelanotide efficacy stratified by age, body weight, BMI, and baseline testosterone levels. The compound demonstrated consistent efficacy across subgroups, suggesting broad applicability within the indicated population.[10]

Koochaki et al. (2021) reported patient experience data from RECONNECT exit surveys, providing qualitative assessment of bremelanotide’s impact on sexual function, relationship satisfaction, and overall quality of life from the patient perspective.[12]

Male Erectile Function Research

Bremelanotide’s initial clinical development included significant investigation in male erectile dysfunction. Diamond et al. (2004) published two key studies evaluating intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. The first established pharmacokinetic and pharmacodynamic profiles, while the second documented dose-dependent improvements in erectile function in a double-blind, placebo-controlled design.[19][20]

Hedlund et al. (2004) reviewed the PT-141 development program at the time, describing the compound’s potential as a nasal spray for treating erectile dysfunction with Phase IIb trials completed, and noting the novel CNS mechanism that differentiated it from existing PDE5 inhibitor therapies.[3]

A particularly notable study by Safarinejad (2008) evaluated bremelanotide in men who had failed sildenafil therapy — a clinically significant population representing unmet medical need. The randomized, double-blind, placebo-controlled trial demonstrated that intranasal bremelanotide improved erectile function in PDE5 inhibitor non-responders, providing clinical evidence that the melanocortin CNS pathway could succeed where peripheral vasodilation failed.[17]

Shadiack et al. (2007) published a comprehensive review of melanocortins in sexual dysfunction treatment spanning both male and female applications, synthesizing the preclinical and clinical evidence base for melanocortin receptor agonists as a therapeutic class.[18]

Safety & Pharmacokinetics

The safety profile of bremelanotide has been extensively characterized across over 40 clinical trials. Clayton et al. (2022) published a comprehensive safety analysis spanning approximately 3,500 subjects across the full clinical development program. The most commonly reported adverse events were nausea (40% vs 1% placebo in controlled trials), flushing (20%), injection site reactions (13%), and headache (11%).[11]

Clayton et al. (2017) conducted a Phase 1 study evaluating the safety and tolerability of bremelanotide co-administered with ethanol in healthy male and female participants. The study addressed a clinically relevant drug-alcohol interaction scenario, demonstrating an acceptable safety profile for concomitant use.[13]

Sauter et al. (2020) developed an ultra-sensitive UHPLC-MS/MS analytical method for bremelanotide quantification, enabling evaluation of oral pharmacokinetic properties. This analytical work contributed to the characterization of the peptide’s absorption, distribution, metabolism, and elimination profile across administration routes.[14]

Nappi et al. (2022) reviewed bremelanotide within the broader context of medical treatments for female sexual dysfunction, evaluating its clinical positioning relative to other pharmacologic options and addressing practical considerations for clinical use.[5]

Multiple review articles have examined bremelanotide from regulatory and clinical perspectives. Dhillon (2019) published the first FDA approval review in Drugs, while Mayer et al. (2020) evaluated the compound as a newly approved therapy in the Annals of Pharmacotherapy, and Edinoff et al. (2022) reviewed the compound’s neurobiological basis in Neurology International.[1][4][15]

Pfaus et al. (2022) published a detailed examination of bremelanotide’s neurobiology in CNS Spectrums, describing the MC4R-mediated dopaminergic mechanisms underlying its effects on sexual desire and the neuroanatomical circuits involved in its therapeutic action.[16]

Summary of Research

PT-141 (bremelanotide) represents one of the most thoroughly characterized peptide compounds in clinical research, with data spanning from early preclinical studies through FDA approval and post-marketing surveillance:

• Melanocortin Pharmacology: Bremelanotide acts centrally via MC3R/MC4R to modulate dopaminergic pathways governing sexual desire and motivation — a fundamentally different mechanism from peripheral vasodilators.[16][18]
• Female HSDD: Two Phase 3 RECONNECT trials demonstrated efficacy for hypoactive sexual desire disorder, with 52-week sustained efficacy in open-label extension.[8][9]
• Male Erectile Function: Clinical trials demonstrated efficacy in erectile dysfunction, including salvage of PDE5 inhibitor non-responders.[17][19]
• Safety Profile: Comprehensive safety analysis across ~3,500 subjects with nausea and flushing as most common adverse events, no new signals with long-term exposure.[11][13]

Bremelanotide received FDA approval in 2019 for HSDD in premenopausal women. Products sold by Improved Peptides are research-grade compounds for research use only and are not the approved pharmaceutical product. Ongoing research continues to explore melanocortin receptor pharmacology across additional therapeutic areas.

Frequently Asked Questions

Citations